Timothy Chevassut

Professor Timothy Chevassut is a leading academic and clinician in haematology, serving as Chair of Haematology at Brighton and Sussex Medical School (BSMS), part of the University of Sussex. He is an honorary consultant at the Royal Sussex County Hospital. His expertise spans clinical haematology, acute myeloid leukaemia (AML), myelodysplastic syndromes (MDS), and epigenetic therapies. He holds academic roles including Director of Clinical Academic Training at BSMS and leads the Cancer Translation Advisory Group (CTAG).

Education: BMBCh (Oxford, 1993), MPH (Harvard, 1998), PhD (Edinburgh, 2006). Fellowships include the Royal College of Pathologists (2010) and Royal College of Physicians (2011). His research focuses on understanding the molecular mechanisms of leukaemogenesis, particularly DNMT3A mutations, and translating discoveries into clinical trials. He leads the Brighton Bone Marrow Tissue Bank and directs early-phase clinical trials targeting AML/MDS therapies.

Teaching: Leads courses on Blood Physiology, Cancer Biology, and Clinical Haematology. Recognized for excellence in teaching, including awards and accolades. Supervises students across BSc, Master’s, and PhD levels. Active in mentoring clinical trainees and academic programs like the Brighton Integrated Academic Training (IAT) Programme.

Awards: University of Sussex Award for Excellence in Teaching, runner-up for Best Teacher on the BMBS course twice. Research grants include funding from Wellcome Trust, Bloodwise, and the University of Sussex.

Research Themes: 1) DNMT3A mutations in AML, 2) histone abnormalities in leukaemia stem cells, 3) epigenetic therapies. Collaborates with institutions globally, including London, Oxford, and the U.S. His lab’s work aims to develop novel treatments for AML/MDS, with a 10-year goal of clinical translation.